Aethlon Medical Inc

Latest Report Overview

Aethlon Medical Inc (AEMD) reported For the quarterly period ended June 30, 2026 (Issuer fiscal Q1 FY2027) revenue of $0 million with diluted EPS of $-4.02 and net income of $-2 million. free cash flow was $-2 million for the period. Management continues to focus on navigating the regulatory landscape to secure necessary approvals for its therapeutic filtration platform, which targets high-acuity disease states. The company maintains a lean operating structure as it balances its R&D requirements with the reality of its limited cash reserves. Liquidity remains the primary management theme, as the company operates with no established commercial revenue streams. Future viability is contingent upon successful clinical outcomes, regulatory progress, and the ability to access sufficient capital markets to fund ongoing operations.

Key Takeaways for Aethlon Medical Inc

• Aethlon Medical remains a clinical-stage entity with $0 revenue for the quarter ending June 30, 2026.
• Reported a net loss of $1.55 million for the fiscal Q1 2027 period, consistent with its ongoing R&D and clinical burn rate.
• Cash position of $4.93 million as of June 30, 2026, highlights persistent liquidity risk given the lack of operating revenue.
• Business model is entirely dependent on regulatory milestones and the ability to secure external equity funding to continue operations.
• No commercial sales of the Hemopurifier were recorded, underscoring the early-stage nature of the company’s path to commercialization.

What Does Aethlon Medical Inc Do?

Aethlon Medical, Inc. is a medical technology company focused on developing the Aethlon Hemopurifier, a proprietary therapeutic filtration technology. The device is designed for the potential removal of viruses, bacteria, and tumor-derived exosomes from the circulatory system in clinical settings. The company's technology platform is intended to treat life-threatening conditions, including viral infections and cancer, by selectively filtering pathogens or disease-associated particles from the blood. The company serves the healthcare industry, specifically targeting segments involving infectious diseases and oncology. Aethlon operates primarily as a research and development entity, with its business activities concentrated on clinical trials, regulatory compliance, and the development of its technology portfolio. At its current stage, the company does not have significant commercial operations, employees, or facilities, and its scale is limited to its research initiatives.

Growth Drivers for Aethlon Medical Inc

• Advancement of clinical trials to generate human efficacy data for the Hemopurifier.
• Securing FDA regulatory clearances or approvals for new indications (e.g., specific viruses or cancer types).
• Potential strategic partnerships with established medical device manufacturers for commercial distribution.
• Expanding the list of target pathogens or tumor-derived markers that the Hemopurifier can filter.